The DOI matches its Crossref record; 587 of the 587 references it cites were found in a registry or an index.
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Open accessAbstract
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
Items 401–587 of 587
Kim, D., Kim, M., Park, H.-B., Kim, K., & Kim, D.-E. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00705 · Cited by 69
Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs
Salerno, D., Brogioli, D., Cassina, V., Turchi, D. M., Beretta, G. L., Seruggia, D., Ziano, R., Zunino, F., & Mantegazza, F. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq597 · Cited by 68
Shang, S., Yang, J., Jazaeri, A. A., Duval, A. J., Tufan, T., Fischer, N. L., Benamar, M., Guessous, F., Lee, I.-Y., Campbell, R. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0215 · Cited by 68
Targeting OCT3 attenuates doxorubicin-induced cardiac injury
Huang, K. M., Thomas, M. Z., Magdy, T., Eisenmann, E. D., Uddin, M. E., DiGiacomo, D. F., Pan, A., Keiser, M., Otter, M., Xia, S. H., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020168118 · Cited by 68
Xie, M., Fu, Z., Cao, J., Liu, Y., Wu, J., Li, Q., & Chen, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.088 · Cited by 66
Debele, T. A., Yu, L.-Y., Yang, C.-S., Shen, Y., & Lo, C.-L. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00856 · Cited by 66
Dhingra, R., Guberman, M., Rabinovich-Nikitin, I., Gerstein, J., Margulets, V., Gang, H., Madden, N., Thliveris, J. A., & Kirshenbaum, L. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz240 · Cited by 66
Tu, Y., Hershman, D. L., Bhalla, K. N., Fiskus, W. C., Pellegrino, C. M., Andreopoulou, E., Makower, D., Kalinsky, K. M., Fehn, K., Fineberg, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3008-5 · Cited by 65
Aldieri, E., Bergandi, L., Riganti, C., Costamagna, C., Bosìa, A., & Ghigo, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9527 · Cited by 65
MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program
Xu, J., Li, L., Xiong, J., denDekker, A. D., Ye, A., Karataş, H., Liu, L., Wang, H., Qin, Z. S., Wang, S., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.8 · Cited by 65
Aydınlık, Ş., Erkısa, M., Cevatemre, B., Sarımahmut, M., Dere, E., Arı, F., & Ulukaya, E. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.11.013 · Cited by 65
A degradable triple temperature‐, pH‐, and redox‐responsive drug system for cancer chemotherapy
Yu, B., Song, N., Hu, H., Chen, G., Shen, Y., & Cong, H. (2018) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36515 · Cited by 65
Tao, L., Wang, S., Jing-Bo, H., Zhang, Y., Rong, H., Liu, X., Wen-Jie, C., & Zhou, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109962 · Cited by 65
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
Demir, S., Boldrin, E., Sun, Q., Hampp, S., Tausch, E., Eckert, C., Ebinger, M., Handgretinger, R., Kronnie, G. T., Wiesmüller, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.199364 · Cited by 64
Nakagawa, M., Emoto, A., Nasu, N., Hanada, T., Kuwano, M., Cole, S. P. C., & Nomura, Y. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64944-9 · Cited by 64
de Smet, M., Hijnen, N. M., Langereis, S., Elevelt, A., Heijman, E., Dubois, L. J., Lambin, P., & Grüll, H. (2013) · Investigative Radiology · doi:10.1097/rli.0b013e3182806940 · Cited by 63
Januchowski, R., Wojtowicz, K., Andrzejewska, M., & Zabel, M. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.09.004 · Cited by 63
Li, P., Tu, M., Ho, P. Y., Jilek, J. L., Duan, Z., Zhang, Q.-Y., Yu, A., & Yu, A. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078741 · Cited by 63
Autophagy, Cell Viability and Chemo-resistance are Regulated by miR-489 in Breast Cancer
Soni, M., Patel, Y., Markoutsa, E., Jie, C.-F., Liu, S., Xu, P.-S., & Chen, H.-X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0634 · Cited by 63
Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer
Zeller, C., & Brown, R. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010375759 · Cited by 62
van Elk, M., Deckers, R., Oerlemans, C., Shi, Y., Storm, G., Vermonden, T., & Hennink, W. E. (2014) · Biomacromolecules · doi:10.1021/bm401904u · Cited by 62
Battista, T., Fiorillo, A., Chiarini, V., Genovese, I., Ilari, A., & Colotti, G. (2020) · Cancers · doi:10.3390/cancers12040887 · Cited by 62
Self-citationAberrant DNA Methylation of ABC Transporters in Cancer
Zappe, K., & Cichna‐Markl, M. (2020) · Cells · doi:10.3390/cells9102281 · Cited by 62
Li, K., Liu, W., Zhao, Q., Wu, C., Fan, C., Lai, H., & Li, S. (2019) · Phytotherapy Research · doi:10.1002/ptr.6353 · Cited by 61
Veitch, Z. W. N., Guo, B., Hembruff, S. L., Bewick, A. J., Heibein, A. D., Eng, J., Cull, S., Maclean, D. A., & Parissenti, A. M. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832c484b · Cited by 60
pH Gradient Reversal: An Emerging Hallmark of Cancers
Sharma, M., Astekar, M. S., Soi, S., Manjunatha, B. S., Shetty, D. C., & Radhakrishnan, R. A. (2015) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892810666150708110608 · Cited by 60
Shi, X., Valizadeh, A., Mir, S. M., Asemi, Z., Karimian, A., Majidina, M., Safa, A., & Yosefi, B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173138 · Cited by 60
Qinghong, S., Gao, S., Lina, S., Yueming, Z., Li, X., Wu, J., He, C., Li, H., & Haifeng, Z. (2015) · Proteome Science · doi:10.1186/s12953-014-0057-y · Cited by 59
Li, Z., Zhao, J., Tikhanovich, I., Kuravi, S., Helzberg, J. H., Dorko, K., Roberts, B., Kumer, S. C., & Weinman, S. A. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.125 · Cited by 59
Noack, A., Gericke, B., von Köckritz‐Blickwede, M., Menze, A., Noack, S., Gerhauser, I., Osten, F., Naim, H. Y., & Löscher, W. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719642115 · Cited by 59
Roseblade, A., Luk, F., Ung, A. T., & Bebawy, M. (2015) · Current Cancer Drug Targets · doi:10.2174/1568009615666150225121508 · Cited by 58
Sorcin, an important gene associated with multidrug-resistance in human leukemia cells
Zhou, Y., Xu, Y., Tan, Y., Qi, J., Xiao, Y., Yang, C., Zhu, Z., & Xiong, D. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.08.024 · Cited by 58
Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells
Genovese, I., Fiorillo, A., Ilari, A., Masciarelli, S., Fazi, F., & Colotti, G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.342 · Cited by 58
Self-citationLiu, C., Hua, X., Guo, C., Yang, Z., Wang, Y., & Wang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1638182 · Cited by 58
Lü, L., Fang, J., Zhao, H., & Ma, X. (2015) · Biotechnology Letters · doi:10.1007/s10529-015-1941-y · Cited by 57
Dexter, D., Reddy, R. K., Geles, K. G., Bansal, S., Myint, M. A., Rogakto, A., Leighton, J. C., & Goldstein, L. J. (1998) · PubMed · Cited by 57
Zheng, T., Wang, J., Song, X., Meng, X., Pan, S., Jiang, H., & Liu, L. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0817-8 · Cited by 56
Aliabadi, H. M., Maranchuk, R. A., Kucharski, C., Mahdipoor, P., Hugh, J. C., & Uludağ, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.012 · Cited by 56
Patel, N., Garikapati, K. R., PANDITA, R. K., Singh, D. K., Pandita, T. K., Bhadra, U., & Bhadra, M. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-02800-2 · Cited by 56
Hassan, S., Peluso, J., Chalhoub, S., Idoux‐Gillet, Y., Benkirane-Jessel, N., Rochel, N., Fuhrmann, G., & Ubeaud-Séquier, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240676 · Cited by 56
Preliminary Clinical Experience with 4’-Epidoxorubicin in Advanced Human Neoplasia
Bonfante, V., Bonadonna, G., Villani, F., & Martini, A. (1980) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-81488-4_24 · Cited by 55
Kibria, G., Hatakeyama, H., Sato, Y., & Harashima, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.047 · Cited by 55
Sparks, H., Kondo, H., Hooper, S., Munro, I., Kennedy, G., Dunsby, C., French, P., & Sahai, E. (2018) · Nature Communications · doi:10.1038/s41467-018-04820-6 · Cited by 54
In vivodisposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters
Durmuş, S., Naik, J., Buil, L. C. M., Wagenaar, E., van Tellingen, O., & Schinkel, A. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.28797 · Cited by 54
Zhao, L., Li, Y., Song, X., Zhou, H., Li, N., Miao, Y., & Li, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11054 · Cited by 54
Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin
Hekmatirad, S., Moloudizargari, M., Moghadamnia, A. A., Kazemi, S., Mohammadnia‐Afrouzi, M., Baeeri, M., Moradkhani, F., & Asghari, M. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692654 · Cited by 54
Chemical Modification as a Probe of the Topography and Reactivity of Horse‐Spleen Apoferritin
Wetz, K., & Crichton, R. R. (1976) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1976.tb10049.x · Cited by 53
Structural basis of Sorcin-mediated calcium-dependent signal transduction
Ilari, A., Fiorillo, A., Poser, E., Lalioti, V. S., Sundell, G. N., Ivarsson, Y., Genovese, I., & Colotti, G. (2015) · Scientific Reports · doi:10.1038/srep16828 · Cited by 53
Self-citationQuest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery
Ojima, I., Wang, X., Jing, Y., & Wang, C. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b01012 · Cited by 53
Sabbatino, F., Conti, V., Liguori, L., Polcaro, G., Corbi, G., Manzo, V., Tortora, V., Carlomagno, C., Vecchione, C., Filippelli, A., et al. (2021) · Life · doi:10.3390/life11020105 · Cited by 53
Chang, D.-K., Li, P., Lu, R., Jane, W., & Wu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083239 · Cited by 52
Rolle, F., Bincoletto, V., Gazzano, E., Rolando, B., Lollo, G., Stella, B., Riganti, C., & Arpicco, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119191 · Cited by 52
Zamparelli, C., Macquaide, N., Colotti, G., Verzili, D., Seidler, T., Smith, G. L., & Chiancone, E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.03.003 · Cited by 51
Self-citationDieudonné, F., Marion, A., Marie, P. J., & Modrowski, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1650 · Cited by 51
Zhang (2010) · Oncology Reports · doi:10.3892/or_00001066 · Cited by 51
Saenz-Ponce, N., Pillay, R. R., de Long, L. M., Kashyap, T., Argueta, C. E., Landesman, Y., Hazar-Rethinam, M. H., Boros, S., Panizza, B. J., Jacquemyn, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7223 · Cited by 51
Liu, R.-M., Xu, P. H., Chen, Q., Feng, S., & Xie, Y. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153342 · Cited by 51
Wang, X., Yan, J., Shen, B., & Wei, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.708066 · Cited by 51
Zhao, Q. S., He, X., Qin, X., Liu, Y., Jiang, H., Wang, J., Wu, S., Zhou, R., Yu, C., Liu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938439 · Cited by 51
Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
Westhoff, M., Faham, N., Marx, D., Nonnenmacher, L., Jennewein, C., Enzenmüller, S., Gonzalez, P., Fulda, S., & Debatin, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083128 · Cited by 50
Veldman, R. J., Zerp, S. F., BLITTERSWIJK, W. J. V., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601581 · Cited by 50
Ding, J., Zhao, Z., Song, J. T., Luo, B., & Huang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy040 · Cited by 50
Abdoul‐Azize, S., Buquet, C., Li, H., Picquenot, J., & Vannier, J. (2018) · Oncogene · doi:10.1038/s41388-018-0329-6 · Cited by 50
MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells
Zangouei, A. S., Alimardani, M., & Moghbeli, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01873-4 · Cited by 50
Ren, C., Li, X., He, B., & Hu, W. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6149 · Cited by 49
Menéndez-Menéndez, J., Hermida‐Prado, F., Granda‐Díaz, R., González, A., Garcia-Pedrero, J. M., Del-Río-Ibisate, N., González-González, A., Cos, S., Alonso‐González, C., & Martínez‐Campa, C. (2019) · Cancers · doi:10.3390/cancers11071011 · Cited by 49
Zhong, J., Sun, P., Xu, N., Liao, M., Xu, C., Ding, Y., Cai, J. L., Zhang, Y., & Xie, W. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113856 · Cited by 49
Lalioti, V. S., Ilari, A., O’Connell, D. J., Poser, E., Sandoval, I. V., & Colotti, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085438 · Cited by 48
Self-citationStatins revert doxorubicin resistance via nitric oxide in malignant mesothelioma
Riganti, C., Orecchia, S., Pescarmona, G., Betta, P. G., Ghigo, D., & Bosia, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21832 · Cited by 48
Shati, A. A. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13225 · Cited by 48
Mirzaei, S., Abadi, A. J., Gholami, M. H., Hashemi, F., Zabolian, A., Hushmandi, K., Zarrabi, A., Entezari, M., Aref, A. R., Khan, H. Z., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174344 · Cited by 48
Yu, M., Lee, C. M., Wang, M., & Tannock, I. F. (2015) · Cancer Science · doi:10.1111/cas.12756 · Cited by 47
Schmidt, J. K., Roti, E. C. R., Ringelstetter, A. K., Khatib, H., Abbott, D. H., & Salih, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142588 · Cited by 46
Mechanisms of Anthracycline-Enhanced Reactive Oxygen Metabolism in Tumor Cells
Doroshow, J. H. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9474823 · Cited by 46
Zhu, K., Yang, Y., Wen, J., Chen, D., Zhu, W., Ouyang, Z., & Wang, W. (2020) · Aging · doi:10.18632/aging.103004 · Cited by 46
Krishnamurthy, K., Vedam, K., Kanagasabai, R., Druhan, L. J., & Ilangovan, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200731109 · Cited by 45
Pang, E., Hu, Y. C., Chan, K. Y. Y., Lai, P. B. S., Squire, J. A., Macgregor, P. F., Beheshti, B., Albert, M., Leung, T., & Wong, N. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700254 · Cited by 45
Przygodzki, T., Sokal, A., & Bryszewska, M. J. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.03.009 · Cited by 45
Sun, S., Hsieh, J., Tsai, S., Ho, Y., Lee, J.-K., & Kao, C. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00356-6 · Cited by 44
Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin
Shahin, M., Soudy, R., El-Sikhry, H. E., Seubert, J. M., Kaur, K., & Lavasanifar, A. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.007 · Cited by 44
Expression of a Multidrug Resistance Gene in Blast Crisis of Chronic Myelogenous Leukemia
Pirker, R., Goldstein, L. J., Ludwig, H., Linkesch, W., Lechner, C., Gottesman, M. M., & PASTAN, I. (1989) · Cancer Communications · doi:10.3727/095535489820875354 · Cited by 44
Zhang, Z.-L., Jiang, Q.-C., & Wang, S. (2017) · Breast Cancer · doi:10.1007/s12282-017-0821-9 · Cited by 44
Liu, J., Chi, D., Pan, S., Zhao, L., Wang, X., Wang, D., & Wang, Y. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.072 · Cited by 44
Identification of the site of adriamycin-activation in the heart cell
Nohl, H. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90257-2 · Cited by 43
Hall, A. E., Lu, W.-T., Godfrey, J. D., Antonov, A. V., Paicu, C., Moxon, S., Dalmay, T., Wilczynska, A., Muller, P. A. J., & Bushell, M. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.91 · Cited by 43
Uceda-Castro, R., Margarido, A. S., Cornet, L., Vegna, S., Hahn, K., Song, J., Putavet, D. A., van Geldorp, M., Çitirikkaya, C. H., de Keizer, P. L. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100821 · Cited by 43
Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties
Vu, N. B., Nguyen, T. T., Tran, L. C.-D., Do, C. D., Bắc, N. H., Phan, N. K., & Pham, P. V. (2012) · Cytotechnology · doi:10.1007/s10616-012-9511-9 · Cited by 42
A Novel E2F/Sphingosine Kinase 1 Axis Regulates Anthracycline Response in Squamous Cell Carcinoma
Hazar-Rethinam, M. H., de Long, L. M., Gannon, O. M., Topkas, E., Boros, S., Vargas, A. C., Dzienis, M. R., Mukhopadhyay, P., Simpson, F., Endo‐Munoz, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1962 · Cited by 42
Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance
Lee, H. H., Leake, B. F., Kim, R. B., & Ho, R. H. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105544 · Cited by 42
He, J., Gong, C., Qin, J., Li, M., & Huang, S. (2019) · Nanoscale Research Letters · doi:10.1186/s11671-019-3143-3 · Cited by 42
Yan, S., Ren, L., Xie, B., Liang, Z. C., & Chen, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21960 · Cited by 41
Liu, W., Zhang, J., Gan, X.-P., Shen, F., Yang, X., Du, N., Xia, D., Liu, L., Qiao, L., Pan, J., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1485 · Cited by 41
Chen, L., Alrbyawi, H., Poudel, I., Arnold, R. D., & Babu, R. J. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1316-0 · Cited by 41
Kim, T. H., Kim, H. S., Kang, Y. J., Yoon, S., Lee, J., Choi, W. S., Jung, J. H., & Kim, H. S. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.11.007 · Cited by 40
Kruczynski, A., Pillon, A., Créancier, L., Vandenberghe, I., Gomes, B., Brel, V., Fournier, E., Annereau, J.-P., Currie, E., Guminski, Y., et al. (2013) · Leukemia · doi:10.1038/leu.2013.108 · Cited by 40
Louisse, J., Wüst, R. C. I., Pistollato, F., Palosaari, T., Barilari, M., Macko, P., Bremer, S., & Prieto, P. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.04.023 · Cited by 40
Dirks‐Naylor, A. J., Kouzi, S. A., Bero, J. D., Phan, D. T., Taylor, H. N., Whitt, S. D., & Mabolo, R. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12073 · Cited by 39
Broxterman, H. J., Sonneveld, P., Pieters, R., Lankelma, J., Eekman, C., Loonen, A. H., Schoester, M., Ossenkoppele, G. J., Löwenberg, B., Pinedo, H. M., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401331 · Cited by 39
Denel‐Bobrowska, M., & Marczak, A. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.04.009 · Cited by 39
Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation
Zhao, Z., Li, R. Q., Sha, S., Wang, Q., Mao, W., & Liu, T. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29923 · Cited by 38
Hochwald, S. N., Rose, D. M., Brennan, M. F., & BURT, M. E. (1997) · Annals of Surgical Oncology · doi:10.1007/bf02303579 · Cited by 38
Role of Oxygen Free Radicals in Cancer Development and Treatment
Pourahmad, J., Salimi, A., & Seydi, E. (2016) · InTech eBooks · doi:10.5772/64787 · Cited by 38
Choupani, J., Alivand, M. R., Derakhshan, S. M., Zaeifizadeh, M., & Khaniani, M. S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27586 · Cited by 38
Panneerpandian, P., Rao, D. B., & Ganesan, K. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105152 · Cited by 38
Expression of Functional Markers in Acute Nonlymphoblastic Leukemia
Han, K., Kahng, J., Kim, M., Lim, J., Kim, Y., Cho, B., Kim, H. K., Min, W. S., Kim, C. C., Lee, K. Y., et al. (2000) · Acta Haematologica · doi:10.1159/000046511 · Cited by 37
Ponnusamy, L., Mahalingaiah, P. K. S., Chang, Y.-W., & Singh, K. P. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.028 · Cited by 37
Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells
Wang, J., Yang, D., Yang, Y., Wang, J., Cai, C., Lei, Z., Teng, Q., Wu, Z., Zhao, L.-G., & Chen, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041387 · Cited by 37
Overcoming Chemoresistance via Extracellular Vesicle Inhibition
Hayatudin, R., Fong, Z., Ming, L. C., Goh, B. H., Lee, W.-L., & Kifli, N. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.629874 · Cited by 37
Mainini, F., Bonizzi, A., Sevieri, M., Sitia, L., Truffi, M., Corsi, F., & Mazzucchelli, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122000 · Cited by 37
Doxorubicin-antioxidant co-drugs
Chegaev, K. Y., Riganti, C., Rolando, B., Lazzarato, L., Gazzano, E., Guglielmo, S., Ghigo, D., Fruttero, R., & Gasco, A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.070 · Cited by 36
miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1
Yu, Z., Xu, Z., DiSante, G., Wright, J. A., Wang, M., Li, Y., Zhao, Q., Ren, T., Ju, X., Gutman, E. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1804 · Cited by 36
miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27kip1 pathway
Wang, D., Yang, S., Chen, X., Shen, H.-Y., Luo, L.-J., Zhang, X., Zhong, S., Zhao, J., & Tang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5341-2 · Cited by 36
Self-resistance mechanisms to DNA-damaging antitumor antibiotics in actinobacteria
Tenconi, E., & Rigali, S. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.03.003 · Cited by 36
Yuan, Y., Yu, H., Mu, S.-M., Dong, Y., & Li, D. Y. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819851833 · Cited by 36
Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR ‐542‐5p
Wang, W., & Zhao, C. (2020) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12322 · Cited by 35
Yi, X., Lou, L., Wang, J., Xiong, J., & Zhou, S. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04238-w · Cited by 35
Doxorubicin and Lovastatin co-delivery liposomes for synergistic therapy of liver cancer
Wang, T., Jiang, Y. X., Chu, H., Liu, X., Dai, Y., & Wang, D. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.04.045 · Cited by 34
Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma
Geng, M., Yang, Y., Cao, X., Dang, L., Zhang, T., & Zhang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.052 · Cited by 34
Zeng, Q., Nie, X., Li, L., Liu, H.-F., Peng, Y.-Y., Zhou, W.-T., Hu, X.-J., Xu, X.-Y., & Chen, X.-L. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00950 · Cited by 33
Mazzanti, R., Platini, F., Bottini, C., Fantappiè, O., Solazzo, M., & Tessitore, L. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.03.013 · Cited by 33
Yang, C., Jiang, F.-Q., Xu, F., & Jiang, G. (2012) · Tumor Biology · doi:10.1007/s13277-012-0405-4 · Cited by 32
Lin, S., Yu, L., Song, X., Bi, J., Jiang, L., Wang, Y., He, M., Xiao, Q., Sun, M., Olopade, O. I., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1871-z · Cited by 32
Bellancé, N., Furt, F., Melser, S., Lalou, C., Thoraval, D. H., Maneta-Peyret, L., Lacombe, D., Moreau, P., & Rossignol, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041317 · Cited by 32
miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells
Jin, Y., Wang, H., Zhu, Y., Feng, H., Wang, G., & Wang, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173105 · Cited by 32
Shen, Q., Yao, Q., Sun, J. L., Feng, L., Lu, H., Ma, Y., Liu, L., Wang, F., Li, J., Yue, Y., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.034 · Cited by 31
Li, L., Wei, X., Wu, B., Xiao, Y., Yin, M., & Yang, Q. (2017) · Oncology Letters · doi:10.3892/ol.2017.5828 · Cited by 31
Multifunctional micelle delivery system for overcoming multidrug resistance of doxorubicin
Qin, L., Wu, L., Jiang, S., Yang, D., He, H., Zhang, F., & Zhang, P. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1379525 · Cited by 31
SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells.
Ll, H., & Rao, W. (2018) · PubMed · doi:10.26355/eurrev_201807_15401 · Cited by 31
Chandra, S., Nguyen, H. M., Wiltz, K., Hall, N., Chaudhry, S., Olverson, G., Mandal, T. K., Dash, S., & Kundu, A. K. (2020) · Journal of Cancer Treatment and Diagnosis · doi:10.29245/2578-2967/2020/1.1176 · Cited by 31
P-Glycoprotein Expression in Bladder Cancer
Park, J., Shinohara, N., Liebert, M., Noto, L., Flint, A., & Grossman, H. B. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)34868-1 · Cited by 30
Li, C., Lai, C., Qiu, Q., Luo, X., Hu, L., Zheng, H., Lü, Y., Liu, M., Zhang, H., Liu, X., et al. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1385-0 · Cited by 30
Licărete, E., Rauca, V. F., Lupuţ, L., Drotar, D. M., Stejerean‐Todoran, I., Pătraș, L., Dume, B. R., Toma, V. A., Porfire, A. S., Gherman, C. D., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082968 · Cited by 30
Structural definition of polyspecific compensatory ligand recognition by P-glycoprotein
Le, C. A., Harvey, D. S., & Aller, S. G. (2020) · IUCrJ · doi:10.1107/s2052252520005709 · Cited by 30
Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization
Mukherjee, S., Adhikary, S., Gadad, S. S., Mondal, P., Sen, S., Choudhari, R., Singh, V., Adhikari, S., Mandal, P., Chaudhuri, S., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03129-x · Cited by 30
CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1
Luo, H., Zhou, Z., Huang, S., Ma, M., Zhao, M., Tang, L., Quan, Y., Zeng, Y., Su, L., Kim, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04114-8 · Cited by 30
Menon, A. V., & Kim, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.817951 · Cited by 30
An Epigenetic Mechanism Underlying Doxorubicin Induced EMT in the Human BGC-823 Gastric Cancer Cell
Han, R., Ji, X., Dong, X., Xiao, R., Liu, Y.-P., Xiong, J., & Zhang, Q. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.10.4271 · Cited by 29
Gene expression alterations in chronic hypoxic MCF7 breast cancer cell line
Hamdan, F. H., & Zihlif, M. (2014) · Genomics · doi:10.1016/j.ygeno.2014.10.010 · Cited by 29
Clifford, S. C., Neal, D. E., & Lunec, J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.115 · Cited by 29
Choi, H. S., Cho, S., Kim, M. K., Kim, M. S., Moon, S. H., Kim, I. H., & Ko, S. (2016) · Phytotherapy Research · doi:10.1002/ptr.5708 · Cited by 29
Engel, D., Nudelman, A., Levovich, I., Gruss-Fischer, T., Entin‐Meer, M., Phillips, D. R., Cutts, S. M., & Rephaeli, A. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0116-6 · Cited by 28
A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells
Wang, L., Chan, J. Y., Zhou, X., Cui, G., Yan, Z., Wang, L., Yan, R., Di, L., Wang, Y., Hoi, M. P. M., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00249 · Cited by 28
Yang, J., Guo, W., Wang, L., Yu, L., Mei, H., Fang, S., Chen, A., Liu, Y., Xia, K., & Liu, G. (2017) · Oncology Letters · doi:10.3892/ol.2017.5708 · Cited by 28
Merino, V. F., Cho, S., Nguyen, N., Sadik, H., Narayan, A., Talbot, C. C., Cope, L., Zhou, X., Zhang, Z., Győrffy, B., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1068-x · Cited by 28
Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin
Azimi, A., Majidinia, M., Shafiei‐Irannejad, V., Jahanban‐Esfahlan, R., Ahmadi, Y., Karimian, A., Mir, S. M., Karami, H., & Yousefi, B. (2017) · Gene · doi:10.1016/j.gene.2017.11.008 · Cited by 27
Waldschmidt, J. M., Keller, A., Ihorst, G., Grishina, O., Müller, S. J., Wider, D., Frey, A. V., King, K., Simon, R. P., May, A. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.189969 · Cited by 27
Wen, Y., Zhao, R.-Q., Gupta, P., Fan, Y., Zhang, Y., Huang, Z., Li, X., Su, Y., Liao, L., Xie, Y.-A., et al. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.10.001 · Cited by 27
Otter, M., Csader, S., Keiser, M., & Oswald, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010255 · Cited by 27
Oxidative stress‐mediated up‐regulation of ABC transporters in lung cancer cells
Yuan, T., Hu, J., Zhu, X., Yin, H., & Yin, J. B. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23095 · Cited by 27
Reversing Effect of Sorcin in the Drug Resistance of Human Nasopharyngeal Carcinoma
Liu, X., Chen, L., Feng, B., & Liu, G. (2013) · The Anatomical Record · doi:10.1002/ar.22832 · Cited by 26
Anticancer activity of 2’-hydroxyflavanone towards lung cancer
Awasthi, S., Singhal, S. S., Singhal, J., Nagaprashantha, L. D., Li, H., Yuan, Y., Liu, Z., Berz, D., Igid, H. P., Green, W. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26329 · Cited by 26
Cai, H., Li, L., Jiang, J., Zhao, C., & Yang, C. (2019) · Phytotherapy Research · doi:10.1002/ptr.6355 · Cited by 26
Yang, J., Wu, S.-P., Wang, W., Jin, Z.-R., Miao, X., Wu, Y., Gou, D., Liu, Q., & Yao, K. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111817 · Cited by 26
Yin, W., Pham, C. V., Wang, T., Shamaileh, H. A., Chowdhury, R., Patel, S., Li, Y., Kong, L., Hou, Y., Zhu, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12111623 · Cited by 26
Ni, W., Chen, B., Zhou, G.-X., Lu, C., Xiao, M., Guan, C., Zhang, Y., He, S., Shen, A., & Ni, R. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24560 · Cited by 25
Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0193-6 · Cited by 25
Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p
Pan, Y., Ren, F., Zhang, W., Liu, G., Yang, D., Hu, J. R., FENG, K., & Feng, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3546 · Cited by 24
Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients
Lasalvia-Prisco, E., Cucchi, S., V�zquez, J. J., Lasalvia-Galante, E., Golomar, W., & Gordon, W. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0716-7 · Cited by 24
microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma
Kwok, G., Zhao, J., Glover, A. R., Gill, A. J., Clifton-Bligh, R. J., Robinson, B. G., Ip, J. C. Y., & Sidhu, S. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0849 · Cited by 24
Lee, W., & Thévenod, F. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.114 · Cited by 24
Potential of Ferritin-Based Platforms for Tumor Immunotherapy
Xu, X., Tian, K., Lou, X.-F., & Du, Y. (2022) · Molecules · doi:10.3390/molecules27092716 · Cited by 24
Wang, J., & Qiu, L. (2022) · Theranostics · doi:10.7150/thno.70852 · Cited by 24
Li, Z., Cheng, G., Zhang, Q., Wu, W., Zhang, Y., Wu, B., Liu, Z., Tong, X., Xiao, B., Cheng, L., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.018 · Cited by 24
Xia, M., Sheng, L., Qu, W., Xue, X., Chen, H., Zheng, G., & Chen, W. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02278-3 · Cited by 23
Inactivation of Anthracyclines by Cellular Peroxidase
Reszka, K. J., Wagner, B. A., Teesch, L. M., Britigan, B. E., Spitz, D. R., & Burns, C. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2312 · Cited by 22
Lei, S., Fan, P., Wang, M., Zhang, C., Jiang, Y., Huang, S., Fang, M., He, Z., & Wu, A. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8809 · Cited by 22
Torigoe, K., Sato, S., Kusaba, H., Kohno, K., Kuwano, M., Okumura, K., Green, E. D., Tsui, L.-C., Scherer, S. W., Schlessinger, D., et al. (1995) · Genome Research · doi:10.1101/gr.5.3.233 · Cited by 20
[ANTHRACYCLINONES AND ANTHRACYCLINES. (RHODOMYCINONE, PYRROMYCINONE AND THEIR GLYCOSIDES)].
Brockmann, H. (1963) · PubMed · Cited by 20
Bao, J., Li, M., Liang, S., Yang, Y., Wu, J., Zou, Q., Fang, S., Chen, S., & Guo, L. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0520-9 · Cited by 20
Jacobs, H., Bast, A., Peters, G. J., van der Vijgh, W. J. F., & Haenen, G. R. M. M. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606065 · Cited by 19
Werner, M., Atil, B., Berger–Sieczkowski, E., Chiba, P., & HOHENEGGER, M. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0859-y · Cited by 19
Kitada, K., & Yamasaki, T. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.06.014 · Cited by 19
Curcumin induces chemosensitization to doxorubicin in Duke’s type B coloadenocarcinoma cell line
Jayarajan, J., Angandoor, S., Vedulla, S. H., Sritharan, S., Ganesan, K., War, A. R., & Sivalingam, N. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05866-w · Cited by 19
Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling pathways
Tito, C., Genovese, I., Giamogante, F., Benedetti, A., Miglietta, S., Barazzuol, L., Cristiano, L., Iaiza, A., Carolini, S., Angelis, L. D., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04850-4 · Cited by 19
Self-citationDoxorubicin combined with Notch1‑targeting siRNA for the treatment of gastric cancer
Zhou, W., Tan, W., Huang, X., & Yu, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9039 · Cited by 18
Hussein, U. K., Ahmed, A. G., Song, Y., Park, S., Kim, K. M., Moon, Y. J., Ahn, A.-R., Park, H. S., Ahn, S. J., Kim, J. R., et al. (2021) · Cells · doi:10.3390/cells10071770 · Cited by 17
The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update
Torki, Z., Ghavi, D., Hashemi, S., Rahmati, Y., Rahmanpour, D., Pornour, M., & Alivand, M. R. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04337-8 · Cited by 17
Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug
Liu, W., Liang, L., Zhao, L., Tan, H., Wu, J., Qin, Q., Gou, X., & Sun, X.-H. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.017 · Cited by 16
Maspin influences response to doxorubicin by changing the tumor microenvironment organization
Triulzi, T., Ratti, M., Tortoreto, M., Ghirelli, C., Aiello, P., Regondi, V., Modica, M. D., Cominetti, D., Carcangiu, M. L., Moliterni, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28608 · Cited by 15
de Moraes, G. N., Castro, C. P., Salustiano, E. J., DUMAS, M. L., Costas, F., Lam, E. W. ‐., Costa, P. R. R., & Maia, R. C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2615 · Cited by 15
Zhang, H., Zheng, X., Zeng, X., Li, L., & Zhou, Q. (2020) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.20-00160 · Cited by 15
The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review
Si, Z., Zhong, Y., Lao, S., Wu, Y., Zhong, G., & Zeng, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.899145 · Cited by 15
Pereira, G. C., Pereira, S. P., Pereira, F. B., Lourenço, N., Lumini‐Oliveira, J., Pereira, C. V., Bjork, J. A., Magalhães, J., Ascensão, A. A. M. R., Wieckowski, M. R., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz026 · Cited by 14
Zhao, H., Zhang, Q., Yang, Y., Lu, M.-Q., Li, H., 徐池, & Chen, G.-H. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i5.683 · Cited by 13
Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Genovese, I., Ilari, A., Battista, T., Chiarini, V., Fazi, F., Fiorillo, A., & Colotti, G. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.10 · Cited by 9
Self-citationChen, X., Qi, F., Shen, A., Chu, J., Sferra, T. J., Chen, Y., & Peng, J. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-2992-4 · Cited by 8
Ordonez, E., Kendrick-Williams, L. L., & Harth, E. M. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.110210 · Cited by 8
Metadata
- Authors
- Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 93
- Pages
- 101205
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W4385325206
- Cited by
- 294
- References
- 587
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.